Hyperthermie in der Onkologie: Eine viel versprechende neue Methode?

Zusammenfassung

Die Hyperthermie ist eine gut untersuchte und viel versprechende innovative Methode in der Krebstherapie, die einen wesentlichen Beitrag zur Verbesserung der Therapieergebnisse in der Krebstherapie leistet. Die Ergebnisse experimenteller und klinischer Studien weisen darauf hin, dass Hyperthermie eine ideale komplementäre Behandlung und ein starker Sensibilisator für die Radio- oder Chemotherapie ist. Neue technische Methoden und umfassende experimentelle und klinische Prüfungen haben die Effizienz dieser Methode demonstriert und rechtfertigen deren Anwendung in der Krebstherapie zum Vorteil der Patienten. Weitere experimentelle und klinische Untersuchungen sind dringend erforderlich. In dem Übersichtsbeitrag werden die Methoden, die Rationale, die klinischen Ergebnisse und die Toxizität der Hyperthermie in der Onkologie dargestellt.

Summary

Hyperthermia is a very promising and established new method in cancer therapy, contributing to a significant improvement of therapeutic efficacy. The results of experimental and clinical trials are demonstrating that hyperthermia is an ideal complementary treatment and strong sensitizer for radioand chemotherapy. New technical methods and comprehensive experimental and clinical trials have demonstrated the efficacy of hyperthermia and justify there use in cancer therapy for the advantage of the patients. Further experimental and clinical researches are urgently warranted. In this review the methods, the rational, the clinical results and toxicity of hyperthermia in oncology are shown.

Schlüsselwörter

Hyperthermie - Thermotherapie - Krebstherapie - Chemotherapie - Strahlentherapie

Keywords

hyperthermia - thermotherapy - cancer therapy - chemotherapy - radiotherapy

Literatur

• 01 Baba H, Siddik Z H, Strebel F R, Jenkins G N, JBull J M. Increased therapeutic gain of combined cis-diamminedichloroplatinum (II) and whole body hyperthermia therapy by optimal heat/drug scheduling.  Cancer Res. 1989;  49 (24 Pt 1) 7041-7044
• 02 Baba H, Stephens L C, Strebel F R, Siddik Z H, Newman R A, Ohno S, Bull J M. Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia.  Cancer Res. 1991;  51 (13) 3568-77
• 03 Baronzio G F, Hager E D. Hyperthermia in Cancer Treatment. A Primer.  Springer/Landes. Bioscience. 2006; 
• 04 Bull J, Scott G L, Graham J L, Strebel F R, Oliver D H, Redwine M D, Koch S M. A New Phase II Clinical Trial for Inoperable or Metastatic Pancreas Cancer Using Fever-Range Whole-Body-Thermal-Therapy (FR-WB-TT) + Cisplatin (CIS) - Gemcitabine (GEM) + Metronomic, Low-Dose Interferon-alpha (IFN-alpha). Annual Meeting of the Society for Thermal Medicine Bethesda/USA; 01.-03..04..2005: 21
• 05 Colombo R, Lev A, Da Pozzo L F, Freschi M, Gallus G, Rigatti P. A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment.  J Urol. 1995;  153 (3 Pt 2) 959-963
• 06 Simone M de, Aimone M, Izzo G. Peritonectomy and hyperthermic antiblastic peritoneal perfusion (HT) for peritoneal carcinomatosis.  J Exp Clin Res. 1997;  16 356-357
• 07 Eddy A H. Alterations in tumour microvasculature during hyperthermia.  Radiology. 1980;  137 (2) 381-5
• 08 Fujimoto S, Takahashi M, Mutou T. et al . Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma.  Cancer. 1999;  85 529-534
• 09 Glehen O, Mithieux F, Osinsky D. et al . Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: A phase II study.  J Clin Oncol. 2003;  21 799-806
• 10 Hager E D, Dziambor H, Strama H, Sueße B. Intraperitoneal hyperthermic perfusion (IPHP) chemotherapy of patients with peritoneal disseminated drug resistant ovarian cancer.  Southern Med J. 1996;  89 (10) 143
• 11 Hager E D, Dziambor H, Höhmann D, Strama H. Prevention of cystectomy of recurrent bladder carcinoma by intravesical hyperthermic perfusion chemotherapy (IVHP).  Anticancer Res. 1998;  18 4876
• 12 Hager E D, Dziambor H, Höhmann D, Mühe N, Strama H. Intraperitoneal hyperthermic perfusion chemotherapy of patients with chemotherapy-resistant peritoneal disseminated ovarian cancer.  Int J Gynecol Cancer. 2001;  11 (S 1) 57-63
• 13 Hager E D, Dziambor H, App E M, Popa C, Popa O, Hertlein M. The treatment of patients with high-grade malignant gliomas with RF-hyperthermia.  Proceedings of ASCO. 2003;  22 118
• 14 Issels R D. High-risk soft tissue sarcoma: clinical trial and hyperthermia combined chemotherapy.  Int J Hyperthermia. 2006;  22 235-239
• 15 Jones E L, Oleson J R, Prosnitz L R, Samulski T V, Vujaskovic Z, Yu D, Sanders L L, Dewhirst M W. Randomized trial of hyperthermia and radiation for superficial tumors.  J Clin Oncol. 2005;  23 3079-3085
• 16 Jones E L. Neoadjuvant Liposomal Doxorubicin (Myocet), Paclitaxel and Hyperthermia in Locally Advanced Breast Cancer. Annual Meeting of the Society for Thermal Medicine Bethesda/USA; April.01-03.2005: 66
• 17 Kinuya S, Yokoyama K, Michigishi T, Tonami N. Optimization of radioimmunotherapy interactions with hyperthermia.  Int J Hyperthermia. 2004;  20 190-200
• 18 Kisailus A, Pitchard M, Li Y, Ostberg J, Reparsky E A. Thermal Regulation of Antigen Presenting Cells: Use of Hyperthermia as an Adjuvant for Cancer Vaccines. Annual Meeting for the Society for Thermal Medicine Bethesda/USA; April.6-8.2006 16
• 19 Kleef R, Hager E D. Fever, Pyrogens and Cancer. In: Baronzio GF, Gramaglia A (ed.): Locoregional Radiofrequency-perfusional and Whole Body Hyperthermia in Cancer Treatment: New Clinical Aspects Eurekah 2005: 62ff
• 20 Ohno S, Strebel F R, Stephens L C, Siddik Z H, Baba H, Makino M, Khokhar A R, Bull J M C. Haematological toxicity of Carboplatin and cisplatin combined with whole body hyperthermia in rats.  Br J Cancer. 1993;  68 469-474
• 21 Ostberg J R, Gellin C, Patel R, Reparsky E A. Regulatory potential of fever-range whole body hyperthermia on Langerhans cells and lymphocytes in an antigen-dependent cellular immune response.  J Immunol. 2001;  167 (5) 2666-2670
• 22 Overgaard J. The current and potential role of hyperthermia in radiotherapy.  Int J Rad Onc Biol Physics. 1989;  16 535-549
• 23 Secord A A, Jones E L, Hahn C A, Petros W P, Yu D, Havrilesky L J, Soper J T, Berchuck A, Spasojevic I, Clarke-Pearson D L, Prosnitz L R, Dewhirst M W. Phase I/II trial of intravenous Doxil® and whole abdomen hyperthermia in patients with refractory ovarian cancer.  Int J Hyperthermia.. 2005;  21 (4) 333-347
• 24 Strebel F R, Proett J M, Rowe R W, Deng W, Bull J M C. Fever-Range Whole Body Thermal Therapy Enhancement of Oxaliplatin Efficacy in Vivo is Schedule Dependant. Annual Meeting of the Society for Thermal Medicine. Bethesda/USA; April.6-8.2006 Poster #35
• 25 Sugarbaker P H, Gianola F J, Speyer J L. et al . Prospective randomized trial of intravenous vs. inteaperitoneal 5-FU patients with advanced primary colon or rectal cancer.  Semin Oncol. 1985;  12 101-111
• 26 Sugarbaker P H. Treamtent of peritoneal carcinomatosis from colon or appendiceal cancer with induction intraperitoneal chemotherapy.  Cancer Treat Res. 1996;  82 317-325
• 27 Zee J van der, Gonzalez D, Rhoon G C van, Dijk J D P van, Putten W L J, Hart A A M. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial.  The Lancet. 2000;  355 1119-1125
• 28 Wondergem J, Stephens L C, Strebel F R, Baba H, Ohno S, Siddik Z H, Newman R A, Bull J M. Effect of adriamycin combined with whole body hyperthermia on tumour and normal tissues.  Cancer Res. 1991;  21 (13) 3559-67

Korrespondenzadresse